Center for Childhood Cancer and Blood Diseases
The mission of the Center for Childhood Cancer and Blood Diseases is to expand the understanding of the pathogenesis of childhood cancer and to improve strategies for diagnosis and treatment.
Our areas of focus include:
- Biology and therapy of rhabdomyosarcoma and other childhood tumors
- Chemotherapy of childhood solid tumors
- Regulation of alternative pre-mRNA splicing
- Regulation and function of tumor suppressor genes
- Oncolytic viral therapy in pediatric brain tumors
- Immunotherapy and cellular therapies that harness the natural ability of the immune system to fight cancers
Affiliations and Collaborations
The Research Institute’s Trainee Association (RITA) was created in 2013 to help better train and prepare trainees for their “next steps.”
We have a purpose for every passion. Join our team and discover your passion for what’s possible in providing best outcomes for children.
Click here to view a list of our current openings at The Research Institute at Nationwide Children's Hospital.
For Patients & Families
Our hematology, oncology, and blood and marrow transplant teams treat patients with all forms of cancer and blood disorders. Our specialists participate in collaborative research across the country and around the world to bring innovative treatments to our patients.
In 1892, a group of citizens held a sale to raise money for the care of sick, impoverished children. That effort led to the opening of Nationwide Children’s Hospital in 1894. For more than a century, we have existed to care for every child, for every reason.
Meet Our Team
Learn more about director Stephen Lessnick, MD, PhD, and his team of principal investigators at the Center for Childhood Cancer and Blood Diseases.
Under the direction of Dawn Chandler, PhD, the Chandler Lab focuses on the regulation of pre-mRNA splicing and its disruption leading to pediatric cancer and spinal muscular atrophy.
Timothy Cripe Lab
Under the direction of Timothy Cripe, MD, PhD, the Cripe Lab focuses on developing and testing new, targeted therapies for pediatric solid tumors and translating those findings into clinical studies.
Peds-ONC Immunotherapy Center
The Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center’s overarching hypothesis is that, in addition to adaptive immunotherapies, innate immune mechanisms of resistance in pediatric cancers can be leveraged as cancer immunotherapeutics.
World-renowned Biopathology Center
The Biopathology Center at Nationwide Children’s Hospital serves as the only pediatric repository for pediatric solid tumor and is one of only two repositories for leukemia samples in the United States, Canada and Australia.